Linden sees 8x return on original HydraFacial investment amid $1.1bn SPAC merger

For Linden, the deal represents the Chicago healthcare specialist's fourth announced exit this year, joining ProPharma Group, Solara and Z-Medica. 

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this